NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Marketwired2 years ago

    Aastrom Biosciences Changes Name to Vericel Corporation

    Aastrom Biosciences, Inc. , a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the change of its corporate name to ...

  • Zacks Small Cap Research2 years ago

    Aastrom Fundamentals Continue To Improve

    We rates shares of Aastrom Biosciences, Inc. (ASTM) a 'Buy' and are adjusting our target to $6.50 per share. Based on industry-average multiples, we see Aastrom's stock doubling in 2015. On November 13, 2014, Aastrom Biosciences reported financial results for the quarter of 2014 ending September 30, 2014. Results in the quarter included a full quarter of operations for the recently acquired Cell Therapy and Regenerative Medicine ("CTRM") business from Sanofi (SNY), previously known as Genzyme Biosurgery Aps.

  • theflyonthewall.com2 years ago

    Aastrom appoints Michel CFO

    Aastrom Biosciences announced the appointment of Gerard Michel as CFO and vice president, corporate development. Michel was formerly CFO and vice president, corporate development of Biodel, where he oversaw ...